Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection
| Autor: | Yoshihiro Isomura, Hiroto Kinoshita, Takanori Kanai, Hidekazu Suzuki, Toshihiro Nishizawa, Akira Toyoshima, Naohisa Yahagi, Osamu Toyoshima, Ai Fujimoto, Shuntaro Yoshida |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Vonoprazan medicine.drug_class Clinical Biochemistry Medicine (miscellaneous) Proton-pump inhibitor macromolecular substances Gastroenterology 03 medical and health sciences 0302 clinical medicine Clarithromycin Internal medicine medicine Nutrition and Dietetics biology medicine.diagnostic_test business.industry Amoxicillin Helicobacter pylori biology.organism_classification Endoscopy Regimen Metronidazole 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Journal of Clinical Biochemistry and Nutrition. 60:208-210 |
| ISSN: | 1880-5086 0912-0009 |
| DOI: | 10.3164/jcbn.16-86 |
| Popis: | The effects of patient age on the efficacy of eradication treatment for Helicobacter pylori (H. pylori) remain unclear. The present study aimed to determine whether age affects eradication therapy involving vonoprazan, a novel potassium-competitive acid blocker (PCAB). We reviewed the cases of 3,261 patients who were administered first-line and second-line H. pylori eradication therapy at Toyoshima Endoscopy Clinic. The first-line treatment was clarithromycin and amoxicillin combined with a proton pump inhibitor (PPI) or a PCAB. The second-line treatment was metronidazole and amoxicillin combined with a PPI or PCAB. The patients were divided into a young to middle-aged group (age ≤50 years) and an older group (age >50 years) as well as into PPI and PCAB groups. The PPI-clarithromycin-amoxicillin regimen demonstrated a significantly lower H. pylori eradication rate than the PCAB-clarithromycin-amoxicillin regimen (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|